KB-1055

JNJ70218902-TMEFF2-hIgG4-S228P

×
Please enable JavaScript in your browser to complete this form.
12083
Home » JNJ70218902-TMEFF2-hIgG4-S228P

Background of JNJ70218902-TMEFF2-hIgG4-S228P

JNJ70218902-TMEFF2-hIgG4-S228P is a bispecific antibody that engages TMEFF2-expressing tumor cells and CD3 on T cells causing exposure dependent pro-inflammatory responses and target tumor cell lysis and promote T cell-mediated killing of tumor cells.

Specifications

Catalog NumberKB-1055
Antibody NameJNJ70218902-TMEFF2-hIgG4-S228P
IsotypeHuman IgG4-S228P, kappa
FC MuationsWild Type
TargetTMEFF2
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Cassandra Lowenstein, Subhasree Basu, Joshua Rusbuldt, et al. 1360 Pharmacodynamics of JNJ-70218902, a TMEFF2×CD3 bispecific antibody, in cynomolgus monkey. Journal for ImmunoTherapy of Cancer 2022; 10: doi: 10.1136/jitc-2022-SITC2022.1360.
  2. Subhasree Basu, Mike Russell, Katrin Sproesser, et al. Abstract LB087:Characterization of JNJ-70218902, a TMEFF2xCD3 bispecific antibody, in prostate cancer models. POSTER PRESENTATIONS-LATE-BREAKING ABSTRACTS, JUNE 15 2022.
Please enable JavaScript in your browser to complete this form.